SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-18-022572
Filing Date
2018-09-04
Accepted
2018-09-04 07:00:38
Documents
5
Period of Report
2018-09-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K agle-8k_20180904.htm 8-K 34541
2 EX-99.1 agle-ex991_327.htm EX-99.1 20029
3 EX-99.2 agle-ex992_312.htm EX-99.2 935
4 GRAPHIC g1we3cb2prhq000001.jpg GRAPHIC 166051
5 GRAPHIC gxnhhz4v4nyu000001.jpg GRAPHIC 3061
  Complete submission text file 0001564590-18-022572.txt   289877
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 181051234
SIC: 2834 Pharmaceutical Preparations